Filing Flows › Comparisons › BOLT vs LYEL
Bolt Biotherapeutics vs Lyell Immunopharma: BOLT and LYEL compared
Bolt Biotherapeutics is the larger company: $5K of revenue in its latest quarter (Q2 2026) against $3K for Lyell Immunopharma (Q3 2026). Lyell Immunopharma is growing faster (-80% against -100% a year earlier).
Where the money goes: BOLT and LYEL
Bolt Biotherapeutics (BOLT) · Q2 2026
Bolt Biotherapeutics, Q2 2026: revenue $5K (-100% year over year), net loss $7.7M, operating cash flow −$6.5M. The chart follows the revenue to costs, profit and cash.
Lyell Immunopharma (LYEL) · Q3 2026
Lyell Immunopharma, Q3 2026: revenue $3K (-80% year over year), net loss $45.5M, operating cash flow −$34.6M. The chart follows the revenue to costs, profit and cash.
| Bolt Biotherapeutics (BOLT) | Lyell Immunopharma (LYEL) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $5K | $3K |
| Revenue growth, Y/Y | -100% | -80% |
| Operating margin | n/m | n/m |
| Net earnings | −$7.7M | −$45.5M |
| Operating cash flow | −$6.5M | −$34.6M |
Questions
Which is bigger, Bolt Biotherapeutics or Lyell Immunopharma?
Bolt Biotherapeutics is the larger company: $5K of revenue in its latest quarter (Q2 2026) against $3K for Lyell Immunopharma (Q3 2026).
Is Bolt Biotherapeutics or Lyell Immunopharma growing faster?
Lyell Immunopharma is growing faster (-80% against -100% a year earlier).
More: Bolt Biotherapeutics earnings · how Bolt Biotherapeutics makes money · Lyell Immunopharma earnings · how Lyell Immunopharma makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 11, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.